Relay Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 9, 2026, for Relay Therapeutics, Inc. (RLAY), a Delaware corporation headquartered in Cambridge, Massachusetts. The filing primarily reports the results of the Company's 2026 Annual Meeting of Stockholders and a subsequent amendment to its Certificate of Incorporation.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Corporate Actions
- Authorized Share Increase: The Company filed a Certificate of Second Amendment to increase its authorized common stock from 300,000,000 shares to 450,000,000 shares.
- Annual Meeting Results: Stockholders voted on four proposals at the meeting held on June 9, 2026:
- Proposal 1 (Election of Directors): Elected Douglas S. Ingram and Claire Mazumdar, Ph.D., to Class III director seats. Both received significant majority support (approx. 82% and 83% of votes cast, respectively).
- Proposal 2 (Say-on-Pay): Stockholders approved the non-binding advisory vote on executive compensation with approximately 97.8% of votes cast in favor.
- Proposal 3 (Auditor Ratification): Ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with approximately 99.9% of votes cast in favor.
- Proposal 4 (Charter Amendment): Approved the increase in authorized shares with approximately 99.5% of votes cast in favor.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The document focuses strictly on the procedural outcomes of the Annual Meeting and the legal filing of the charter amendment.
Investor Verification Checklist
- Verify the impact of the increased authorized share count (450 million) on potential future dilution.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 28, 2026) for detailed biographies of the newly elected directors and executive compensation specifics.
- Confirm the effective date of the Certificate of Second Amendment with the Delaware Secretary of State records.
- Check subsequent filings (e.g., 10-Q or 10-K) for the actual financial performance data not included in this 8-K.